BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

ROCKVILLE, Md. and SUZHOU, China, Sept. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical ...

One of the current challenges of immunotherapy is the hunt for good targets, and the Claudins – a family of roughly two dozen ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...